Article
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
On October 3, Eli Lilly and Company and POINT Biopharma Global, Inc. announced their definitive agreement, under which Lilly will acquire POINT, aiming to strengthen their presence in cancer therapeutics leveraging POINT’s radioligand therapies.
On October 3, Eli Lilly and Company and POINT Biopharma Global, Inc. announced their definitive agreement, under which Lilly will acquire POINT, aiming to strengthen their presence in cancer therapeutics leveraging POINT’s radioligand therapies. The acquisition is valued at around USD 1.4 billion.
POINT Biopharma is a radiopharmaceutical company with pipeline of clinical and preclinical stage radioligand therapies for cancer treatment. Radioligand therapy links a radioisotope to a targeting molecule and helps in precise targeting of cancer. The direct radiation to cancer cells enables significant anti-tumour efficacy.
As per the terms of the agreement, Lilly will initiate a tender to acquire all outstanding shares of POINT at a cost price of USD 12.50 per share (in cash). This turns out to be an aggregate of USD 1.4 billion. The board of directors from both companies have approved the entire transaction and it is estimated to close by the end of 2023. This includes getting an approval from the U.S. Nuclear Regulatory Commission for license transfer as well.
The purchase price is an 87% premium to POINT’s closing stock value on October 2. It is 68% premium with respect to the 30-day volume-weighted average price. Therefore, POINT’s board of directors have recommended the stockholders to tender their shares in the tender offer. In this acquisition, Goldman Sachs & Co. LLC is acting as the exclusive financial advisor for Lilly, while Centerview Partners LLC is operating as POINT’s financial advisor.
Currently, POINT’s PNT2002– a prostate-specific membrane antigen (PSMA) targeted radioligand therapy program, is in the late phase development. The topline data is expected to arrive by the fourth quarter of 2023. They are also working on gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a somatostatin receptor targeted radioligand therapy (PNT20031).
POINT has a 180,000 square foot manufacturing base in Indianapolis and a radiopharmaceutical research facility in Toronto. On the day of the agreement, Joe McCann, Ph.D., CEO of POINT, said, “The combination of POINT's team, infrastructure and capabilities with Lilly's global resources and experience could significantly accelerate the discovery, development and global access to radiopharmaceuticals.”
For Lilly, this acquisition is a road map to compete with other radiopharmaceuticals players like Novartis. Notably, Novartis has demonstrated successful outcomes of their radioligand therapy Lutathera (lutetium Lu 177 dotatate), the Phase III NETTER-2 trial in GEP-NETs. Similarly, RayzeBio is also developing a treatment for GEP-NETs with RYZ101, which begun its phase III trials in May 2023.
Indianapolis based Eli Lilly and Company has served approximately 51 million people across the globe for over 150 years. This acquisition represents one of their many strategic partnerships to pioneer in the cancer therapeutics field this year. In addition to acquiring POINT, they have completed a significant USD 2.4 billion buyout of Dice Therapeutics and made a USD 1.93 billion purchase of the privately held Versanis.
Jacob Van Naarden, President of the oncology unit at Lilly, added “We look forward to welcoming POINT colleagues to Lilly and working together to build upon their achievements as we develop a pipeline of meaningful new radioligand treatments for patients.”
Latest Updates on Thriving Economically in a World of Constant Innovation
To place an order through our website, select the license type mentioned on the report details page. Click on the ‘Buy Now’ button and fill in your details. Select your preferred mode of payment after which you will be redirected to the selected payment gateway. Follow the steps and proceed to checkout.
www.expertmarketresearch.comEnlisting all your requirements and queries along with details that include billing and delivery address and the preferred payment mode. Our customer service representative will revert to you within 24 hours.
[email protected]To place an order through telephone, call our sales team on the following numbers and our customer service representative will help you regarding the same.
+61 291 889 415United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124